Oncology · 2007 · 67 citations · 18 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyNeuro-oncologyCentral Nervous System Tumor PharmacotherapyChemotherapy Toxicity ManagementGlioblastomaOncology PharmacologyPharmacodynamics Of Anticancer AgentsToxicity ManagementGlioblastoma ChemotherapyGlioblastoma Clinical TrialsGlioma ChemotherapyImmunohistochemical StainingPeroxisome Proliferator-activated Receptor SignalingPeroxisome Proliferator-activated ReceptorsPhase Ii InvestigationTemozolomide Therapy
OBJECTIVES: Combined treatment approaches targeting tumor as well as other cells contributing to tumor progression may control chemorefractory malignancies. METHODS: A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy (capecitabine or temozolomide) in patients with high-grade gliomas (glioblastoma or anaplastic glioma). RESULTS: Fourteen patients were evaluable for response and toxicity. Major side effects were palmoplantar erythema, edema and motor neuropathy grade 3. Disease stabilizations lasting longer than 3 months were noted in 4 of 14 patients (29%). Clinical responses did not correspond to immunohistochemical staining for cyclooxygenase 2, peroxisome proliferator-activated receptor-gamma and CD31. DISCUSSION: The study demonstrates that this novel regimen is moderately active and well tolerated in patients with high-grade gliomas. As a comparably small proportion of patients responded, the regimen might only be suitable for a subset of highly selected patients.
18
N.K. Aaronson, Sam H. Ahmedzai, Bengt Bergman et al. · JNCI Journal of the National Cancer Institute · 1993 · 16K citations
Response criteria for phase II studies of supratentorial malignant glioma.
David R. Macdonald, T L Cascino, S. Clifford Schold et al. · Journal of Clinical Oncology · 1990 · 2.4K citations
Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.
Tadahisa Shono, Philip J. Tofilon, J. M. Bruner et al. · PubMed · 2001 · 304 citations